Monday, May 10 – Tuesday, May 11, 2021
Tremendous scientific advancements over the last decade indicate that GPCR physiology and pharmacology are much more complex than originally thought and that it may be possible to exploit this complexity to treat a wide variety of diseases. The objective
of this colloquium is to expose scientists to recent discoveries and multidisciplinary approaches used to study GPCRs and provide opportunities for establishing collaborations that bridge complementary interests. The event will feature speakers who
have made exciting discoveries in GPCR research that range from molecular to systems biology, basic research to translational studies, and pharmacology to biochemistry to physiology.
Tracy M. Handel – University of California, San Diego
Paul Insel – University of California, San Diego
Jennifer Pluznick - Johns Hopkins University School of Medicine
Brian Kobilka - Stanford University
Structural Insights into the Dynamic Process of G Protein–Coupled Receptor Activation
Systems Biology Approaches to GPCR Physiology and Pharmacology
Mark Knepper – NHLBI
V2R-omics: Multi-systems Approaches to Define Vasopressin Action
Nina Wettschureck – Max Planck Institute for Heart and Lung Research
Single Cell Analysis of GPCR Expression: Implication for Physiology and Pathophysiology
Kirill Martemyanov - The Scripps Research Institute
Deciphering Diversity of GPCR Signaling
Sriram Kosuri - Univ. of California, Los Angeles
Combining Synthesis and Multiplexed Assays to Explore Human Biology: GPCRs as a Paradigm
GPCR Structural Biology and Drug Discovery
Chris Tate – Cambridge Univ.
Molecular Basis for High-affinity Agonist Binding at the Beta1-adrenoceptor
Bryan Roth – Univ. of North Carolina
New Technologies for Structure-guided GPCR Drug Discovery
Minghong Ma – Univ. of Pennsylvania
G Protein–Coupled Olfactory Receptors: Novel Insights into Responsiveness and Mechano-Sensitivity
Laura Wingler – Duke Univ.
Molecular Mechanisms of Biased Signaling at the Angiotensin Receptor
GPCRs in Pathophysiology and Pathobiology
Jerold Chun - Sanford Burnham Prebys.
SIP, LPA and Their Receptors in CNS Disorders
Kathleen Caron – Univ. of North Carolina
Novel Regulatory Functions of GPCRs in Vascular Growth and Remodeling
Willis (Rick) Samson – St. Louis Univ.
Novel Peptide-activated (Orphan) GPCRs: New Insights and Therapeutic Opportunities
Lora Heisler – Univ. of Aberdeen
Targeting GPCRs to Improve Obesity
Virtual posters at the Colloquium will include a PDF poster with a 5-minute audio narration by the author as well as a text-based Q&A discussion board.
All abstracts submitted during the regular submission period to the topic category “3016-ASPET GPCR Colloquium” will be reviewed and considered for inclusion at the Colloquium. Accepted abstracts will be programmed at both the main EB
meeting and the GPCR Colloquium.
Abstracts can also be submitted from January 14 to February 4, 2021 during the Last-Chance abstract submission period to any ASPET topic category. Please use GPCR as one of your keywords.
If you already submitted or plan to submit to another topic category or society, please email email@example.com with your abstract ID number and we can be sure you are considered for both the Colloquium and EB. Please do not submit duplicate abstracts.
Thanks to the generosity of our sponsors and support from ASPET, ASBMB, and APS, a ticket for the colloquium is being provided at no extra charge with your paid registration to Experimental Biology.
Society Partner Support
American Society for Pharmacology and Experimental Therapeutics
American Society for Biochemistry and Molecular Biology
American Physiological Society
Gold Level Support
Arena Pharmaceuticals, Inc.
British Journal of Pharmacology
Bronze Level Support
Journal of Biological Chemistry
ASPET Division Support
Division for Molecular Pharmacology
Division for Drug Discovery and Development
Division for Neuropharmacology